Ergoteles’s Standard BioTools LAB Stock Holding History

Ergoteles’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,319	Closed	-$21.4K	–	1521
2022 Q4	$21.4K	Sell	18,319 -178,578	-91%	-$220K	﹤0.01%	1344
2022 Q3	$217K	Sell	196,897 -151,503	-43%	-$229K	0.01%	1137
2022 Q2	$557K	Buy	+348,400	New	+$862K	0.02%	795
2022 Q1	–	Sell	-54,948	Closed	-$215K	–	1441
2021 Q4	$215K	Buy	+54,948	New	+$257K	0.01%	997
2021 Q1	–	Sell	-83,400	Closed	-$500K	–	938
2020 Q4	$500K	Buy	+83,400	New	+$548K	0.02%	449

Other funds holding LAB

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Ergoteles's LAB Position: Q1 2023 in Review

Ergoteles sold out of Standard BioTools (LAB) in Q1 2023, closing a stake of 18,319 shares — an estimated $21.4K sold.

Ergoteles first reported a position in LAB in Q4 2020 and held it in 5 quarters. The position peaked at $557K in Q2 2022. 69 funds tracked by Wall St. Rank hold LAB as of Q1 2023.

Ergoteles reported no remaining Standard BioTools position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 18,319 Standard BioTools shares in Q1 2023, an estimated $21.4K.
Ergoteles first reported a position in Standard BioTools in Q4 2020 and held it in 5 quarters.
Ergoteles's Standard BioTools position peaked at $557K in Q2 2022.
69 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.